NAIROBI, Kenya – The government has stepped up efforts to expand local vaccine manufacturing through deeper collaboration with the U.S. Centers for Disease Control and Prevention (CDC) and key national health institutions.
Health Principal Secretary for Medical Services Dr. Ouma Oluga on Tuesday held talks with Dr. Emmanuel Nzani, Chairperson of the Kenya Vision 2030 Delivery Board, and Dr. Charles Githinji, Chairperson of the Kenya Biovax Institute Board, at Afya House in Nairobi.
The meeting focused on strategies to strengthen local vaccine production and reduce Kenya’s dependence on imported health commodities.
Dr. Oluga said the initiative builds on earlier discussions held in Washington, D.C., underscoring the government’s resolve to make Kenya a regional hub for vaccine research, development, and manufacturing.
“The government is committed to achieving self-reliance in vaccine production as part of our broader goal of ensuring equitable access to essential health products,” Dr. Oluga said.
𝐆𝐨𝐯𝐞𝐫𝐧𝐦𝐞𝐧𝐭 𝐃𝐞𝐞𝐩𝐞𝐧𝐬 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐭𝐨 𝐄𝐧𝐡𝐚𝐧𝐜𝐞 𝐋𝐨𝐜𝐚𝐥 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠The Ministry of Health is advancing plans to strengthen local vaccine manufacturing through enhanced collaboration with the U.S. Centers for
The talks also aligned with Kenya’s Vision 2030 framework, which identifies biotechnology and pharmaceutical manufacturing as key drivers of the country’s long-term development goals.
Kenya Biovax Institute, established in 2021, has been spearheading the government’s agenda to produce vaccines locally and strengthen preparedness for future public health emergencies.
